BioMarin Pharmaceutical (BMRN) closed at $54.67 on Oct 19, 2026, down 0.0% on the day. The stock is down 14.5% over the past month, down 7.7% over three months, down 8.0% year to date and up 3.2% over the past year. It trades 23.0% below its 52-week high of $70.98 and 11.0% above its 52-week low of $49.26. The close sits below its 50-day moving average ($62.77) and below its 200-day moving average ($58.54).
NextPick tracks BMRN in its Biotech basket alongside VRTX, MRNA, REGN, BIIB and ALNY. As of Oct 19, 2026, the basket's money-flow score is -20 (weak outflow), and the basket is down 1.1% over five sessions. Over the past month BMRN ranks 16th of 17 basket members by price change.
No — the Oct 19, 2026 close of $54.67 is 6.6% below the 200-day average of $58.54.
BMRN closed 23.0% below its 52-week high of $70.98.
NextPick groups BMRN with VRTX, MRNA, REGN, BIIB and ALNY in its Biotech basket.
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
